Stryker Corporation
SYK Healthcare Medical Devices
Stryker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $25.1 billion, up 11.2% from fiscal 2024. In the quarter to June 2026, revenue grew 9.42%, EPS grew 43.1%, free cash flow grew 14.1% and total debt fell 9.88%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for five, operating cash flow growth for three.
Follow SYK
Stryker Corporation (SYK) EBITDA
Stryker Corporation's EBITDA for fiscal 2025 was $6.1B, up 28.3% from $4.7B in fiscal 2024. Over the twelve months to 30 June 2026 it was $6.8B. Over the past ten years it has ranged from $2.3B (fiscal 2015) to $6.1B (fiscal 2025) — the current reading is the highest in ten years. Stryker Corporation ranks 3rd of 147 Medical Devices companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $6.1B | 28.34% |
| FY2024 | $4.7B | (3.60%) |
| FY2023 | $4.9B | 28.05% |
| FY2022 | $3.8B | 7.41% |
| FY2021 | $3.6B | 17.76% |
| FY2020 | $3.0B | (13.06%) |
| FY2019 | $3.5B | 7.09% |
| FY2018 | $3.3B | 10.92% |
| FY2017 | $2.9B | 8.01% |
| FY2016 | $2.7B | 20.50% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $2.0B | 58.17% |
| Mar 2026 | $1.2B | (41.70%) |
| Dec 2025 | $2.1B | 46.81% |
| Sep 2025 | $1.4B | 2.48% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ABT Abbott Laboratories compare | $10.8B |
| MDT Medtronic PLC compare | $9.7B |
| SYK Stryker Corporation | $6.8B |
| BSX Boston Scientific Corporation compare | $5.6B |
| PHG Koninklijke Philips N.V. compare | $3.4B |
| GEHC GE HealthCare Technologies Inc. compare | $3.3B |
| STE STERIS plc compare | $1.6B |
| EW Edwards Lifesciences Corporation compare | $1.6B |
| DXCM DexCom, Inc. compare | $1.4B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on SYK
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement